Adherium, AstraZeneca (AZN) Enter Smartinhaler Platform Supply Agreement
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
AZNAdherium Limited announced that Adherium will provide Smartinhalers for an AstraZeneca Australia commercial pilot program in 2016. The program will use Adherium’s devices, mobile app and cloud platform and aims to show how these devices improve medication adherence in patients with asthma and chronic obstructive pulmonary disease (COPD).
“This program is an important milestone; adherence rates in patients with asthma or COPD are low, and clinical trials have demonstrated that our platform can make a significant difference for patients and health care professionals. Adherium is supplying the technology for this program under a long-term Master Supply and Development Agreement already entered into with AstraZeneca,” said Garth Sutherland, Adherium’s Group CEO.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Navient (NAVI) Rejects CFPB Ultimatum to Settle
- Ayretrade, Inc. (SUMM) Appoints David Roblin as COO
- McKesson in record $150 million U.S. settlement over suspicious drug orders
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!